个体化癌症疗法 z-bo 2020-10-23 323

　　Researchers from the University of California, San Diego School of Medicine reported that for patients receiving advanced cancer treatment at the Moores Cancer Center of UC San Diego Health, if they receive personalized cancer treatment, they are more likely to have prolonged survival and disease. Progressive relief.

　　Article author Kurzrock said: “Patients recommended by the Molecular Oncology Committee have greatly improved their outcomes after receiving treatment. The three-year survival rate of patients with the highest matching degree and receiving personalized cancer treatment is about 55%, while those who receive no 25% of patients with matching or low matching."

　　related results were published in the recent "Nature Communications" magazine. In this study, 62% of the 429 patients evaluated by the Molecular Oncology Committee matched at least one drug. 20% of patients matched all recommended drugs, including combination therapy.

　　The tumor committee plays a consulting role. The treating doctor chooses not to use the recommended strategy of the committee in 38% of cases, but chooses a standard treatment method that may not match the patient's genetic changes or has a low degree of matching. The progression-free survival and overall survival rate of these patients is low.

　　Shumei Kato, MD, associate professor at the University of California, San Diego School of Medicine, said that the use of next-generation sequencing technology can identify new potential targets for cancer patients, thereby improving treatment effects, but widespread use of this method poses challenges.

　　"One obstacle is that despite the same type of cancer, each cancer patient seems to have a different molecular and genomic pattern. Because we tailor the treatment to the patient’s unique genomic pattern, it is difficult to predict the efficacy. In addition, this method requires more Discipline expertise and access to drugs or clinical trials, which are not always the case."